Executive interview – Volition Rx

Executive interview – Volition Rx

Volition America, a wholly owned subsidiary of VolitionRx Limited, announces a major new colorectal cancer screening trial with 13,500 patients. In collaboration with the Great Lakes New England Clinical Validation Center and funded by the US National Cancer Institute’s (NCI) Early Detection Research Network (EDRN), this clinical study will seek to validate a panel of biomarkers that include Volition’s Nu.Q Colorectal Cancer Screening test in a large asymptomatic population to support US regulatory approval.


You may also be interested in these:

Screenshot 2024-07-01 133526

Real Estate

Regional REIT - executive interview

Industrials

Electro Optic Systems – Brand video

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free